ID   A549(VP)28
AC   CVCL_4V07
DR   cancercelllines; CVCL_4V07
DR   Wikidata; Q54607060
RX   PubMed=1717144;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 10
//
RX   PubMed=1717144;
RA   Long B.H., Wang L., Lorico A., Wang R.C.-C., Brattain M.G.,
RA   Casazza A.M.;
RT   "Mechanisms of resistance to etoposide and teniposide in acquired
RT   resistant human colon and lung carcinoma cell lines.";
RL   Cancer Res. 51:5275-5283(1991).
//